CompletedPhase 2NCT03391804
Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
Studying Primary hyperoxaluria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Allena Pharmaceuticals
- Principal Investigator
- David Clark, MD, M.DAllena Pharmaceuticals Inc
- Intervention
- ALLN-177(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2018 – 2019
Study locations (9)
- Mayo Clinic, Scottsdale, Arizona, United States
- Applied Research Center of Arkansas, Little Rock, Arkansas, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Charite Campus Berlin-Mitte, Medizinische Klinik mit Schwepunkt Nephrologie und Internistische Intensivmedizin, Berlin, Germany
- Wellcome Trust Clinical Research Facility, Southampton, Hampshire, United Kingdom
- Royal Preston Hospital, Preston, Lancashire, United Kingdom
- Leeds General Infirmary, Leeds, United Kingdom
- Freeman Hospital, Newcastle, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03391804 on ClinicalTrials.govOther trials for Primary hyperoxaluria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06839235Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)Arbor Biotechnologies
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06892301Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)Guangzhou Women and Children's Medical Center
- RECRUITINGEARLY PHASE1NCT06511349Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)RenJi Hospital
- RECRUITINGNCT06225882Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.Hospices Civils de Lyon
- ACTIVE NOT RECRUITINGNCT04982393BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)Alnylam Pharmaceuticals
- RECRUITINGPHASE2NCT04580420Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRDDicerna Pharmaceuticals, Inc., a Novo Nordisk company